The cost of treating chronic hepatitis C with sofosbuvir/ledipasvir (Harvoni) with or without ribavirin is lower than the cost of prior interferon-based therapy with first-generation direct-acting antivirals, in part because the newer regimen is well-tolerated and requires less management of side effects, according to a Kaiser Permanente study presented at Digestive Disease Week 2016 last month in San Diego.
